Cogent Biosciences, Inc. (COGT) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Waltham, MA, 미국. 현재 CEO는 Andrew R. Robbins.
COGT 을(를) 보유 IPO 날짜 2018-03-29, 205 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $5.92B.
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company's lead product candidate, CGT9486, is a selective tyrosine kinase inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors by targeting specific KIT mutations. Cogent also holds a licensing agreement with Plexxikon Inc. for the development and commercialization of bezuclastinib. Headquartered in Cambridge, Massachusetts, the company was founded in 2014 and rebranded from Unum Therapeutics Inc. to Cogent Biosciences, Inc. in October 2020.
